Thiazolidinediones
Rosiglitazone (Avandia) and pioglitazone (ACTOS) are in a group of drugs called thiazolidinediones. These drugs help insulin work better in the muscle and fat and also reduce glucose production in the liver. The first drug in this group, troglitazone (Rezulin), was removed from the market because it caused serious liver problems in a small number of people. So far rosiglitazone and pioglitazone have not shown the same problems, but users are still monitored closely for liver problems as a precaution. Both drugs appear to increase the risk for heart failure in some individuals, and there is debate about whether rosiglitazone may contribute to an increased risk for heart attacks. Both drugs are effective at reducing A1C and generally have few side effects.
Most important information about Actos
More information about ACTOS (Pioglitazone):
Actos Benefits Recent Heart-Attack Patients with Diabetes
Actos found to improve glucose control and lipid profiles
Takeda Revises Actos (pioglitazone HCl) Prescribing Label
New Analyses Show Actos Reduced Risk of Secondary Stroke by Almost 50 Percent
ACTOS (Pioglitazone) Combination Therapy
Termination of Development of Fixed Dose Combination Product of Actos + TAK-536
Takeda Wins Patent Infringement Litigation on Appeal Against ANDA Filers for Generic Actos
Diabetes Drugs Increase Risk of Heart Failure, Research Shows
To get more information about Actos: ACTOS MEDICATION.
To buy ACTOS click HERE: My Family Drugstore
Tags: Actos (Pioglitazone), Conditions & Treatments, Medications, Type 2 Diabetes